key: cord-0692116-xc50ihl1 authors: Limon-de la Rosa, Nathaly; Cervantes-Alvarez, Eduardo; Navarro-Alvarez, Nalu title: Increased hepatic expression of SARS-CoV-2 entry points and pro-inflammatory cytokines in cirrhosis date: 2021-09-02 journal: Clin Gastroenterol Hepatol DOI: 10.1016/j.cgh.2021.08.053 sha: 49ed9977e21d8ffbddb29ff307120d48d9559202 doc_id: 692116 cord_uid: xc50ihl1 It has been recently reported that patients with cirrhosis have significantly higher mortality following severe acute respiratory syndrome coronavrisu 2 (SARS-CoV-2) infection compared with those without.1,2 Specifically, it was demonstrated that mortality was greater in those with advanced cirrhosis (Child-Pugh B and C), and that from cirrhotic patients experiencing SARS-CoV-2 infection, close to half suffer acute decompensation including acute-on-chronic liver failure (ACLF).2 Unfortunately, the presence of hepatic decompensation at baseline has been shown to be an independent predictor of all-cause mortality in patients with coronavirus disease 2019 (COVID-19).1 Patients with decompensated cirrhosis contracting COVID-19 have a poor outcome, with an overall reported mortality of over 30%.1. It has been recently reported that patients with cirrhosis have significantly higher mortality following SARS-CoV-2 infection compared to those without 1, 2 . Specifically, it was demonstrated that mortality was greater in those with advanced cirrhosis (Child-Pugh B and C), and that from cirrhotic patients experiencing SARS-CoV-2 infection, close to half suffer acute decompensation including acute-on-chronic liver failure (ACLF) 2 . Unfortunately, the presence of hepatic decompensation at baseline has been shown to be an independent predictor of all-cause mortality in patients with COVID-19 1 . Patients with decompensated cirrhosis contracting COVID-19 have a poor outcome, with an overall reported mortality of over 30% 1 . It is believed that the higher cytokine production and endotoxemia already present in patients with cirrhosis 3 leads to an amplified inflammatory response following an infection and thus could put them at higher risk of adverse outcomes following SARS- COVID-19 is characterized by the release of pro-inflammatory cytokines such as IL-6, IL-8 and MCP-1, which have also been proposed as biomarkers of COVID-19 disease severity 4, 5 and at the same time, are involved in the dysregulated immune responses during advanced cirrhosis. Whether it is the underlying chronic inflammation, the presence of an increased expression of SARS-CoV-2 entry sites in the liver of these patients, or a combined effect, what contributes to the observed increased mortality is not really known. Based on the above discussion, we sought to analyze the hepatic expression of ACE2, TMPRSS2, IL-6, IL-8, and MCP-1 in patients with cirrhosis to provide insight into a potential mechanism that predisposes them to severe COVID-19 and higher mortality. ACE2 and TMPRSS2 mRNA expression was evaluated in 115 liver samples (79 cirrhotic patients and 36 controls) (see Table S1 for detailed characteristics). We categorized cirrhotic patients by disease stage into compensated (CC) n=8, decompensated (DC) n=36, or acute-on-chronic liver failure (ACLF) n=35. Liver mRNA of both ACE2 (P < .0001) and TMPRSS2 (P < .01) was significantly upregulated in J o u r n a l P r e -p r o o f patients with cirrhosis when compared to non-cirrhotic patients (Fig. 1A ) and from those, decompensated patients had the highest expression (Fig. 1B) . It is known that the virus depends on both ACE2 and TMPRSS2 to invade host cells 6 and in the liver, ACE2 is expressed mainly by biliary epithelial cells 7 . Patients with cirrhosis, especially in the most advanced stages, have increased proliferation of biliary epithelial cells in the form of ductular reactions 8 . Our results indicate that both receptors are significantly increased in cirrhosis and even more in decompensated cirrhosis. Furthermore, we found a very good correlation between ACE2 and TMPRSS2 (r= 0.73, P < .0001) (Fig. 1C) . Thus, it is reasonable to speculate that patients with advanced cirrhosis might be at risk of an added viral load due to an augmented viral access to the hepatobiliary system mediated through these two receptors. In fact, autopsies from patients with SARS-CoV2 infection, have shown the presence of viral particles in the liver tissue accompanied by an important inflammatory infiltration with prominent bile duct damage 9 . Given that sex influences immune responses to viruses, we analyzed men and women separately. The hepatic expression of both proteins ACE2 and TMPRSS2 was not statistically different (data not shown), suggesting that if infected, cirrhotic patients would be at equally high-risk of severe COVID-19 regardless of sex. An intriguing part of COVID-19 and the liver involvement has been that the abnormalities observed in the liver biochemistries are mostly indicative of a hepatocellular pattern. It has been postulated that this could be multifactorial, including an immune-mediated inflammatory response 10 . To investigate if cirrhotic patients, besides the well-known underlying systemic inflammation 3 , also have an underlying intrahepatic inflammation, we measured the mRNA hepatic expression of three well-known cytokines/chemokines associated with inflammation and recruitment of macrophages/neutrophils, IL-6, IL-8 and MCP-1 4,5 . We found that mRNA expression of all three molecules was significantly upregulated in cirrhotic patients when compared to non-cirrhotic controls (P < 0.0001) (Fig. 1D ), J o u r n a l P r e -p r o o f indicating that indeed patients with cirrhosis have an important underlying intrahepatic inflammatory state. Such cytokines could not only promote and perpetuate further inflammation in the liver but could also contribute through spillover to the systemic inflammation in these patients. In addition, we found significantly positive correlations between ACE-2 and TMPRSS2 with each of those inflammatory markers ( Suppl Fig 1 A, B) . Thus, when SARS-CoV-2 enters the liver of a cirrhotic patient facilitated by the high expression of ACE-2 and TMPRSS2, and encounters this inflammatory environment, the likelihood of having an uncontrolled inflammatory response to it, is very high. This could induce hepatocyte collateral damage causing the very commonly observed increases of AST and ALT, and further aggravate the already present systemic inflammation in cirrhotic patients 3 . And more importantly, this cascade could also lead to decompensation events and organ failure resulting in ACLF. In conclusion, our results indicate that cirrhotic patients have a significant hepatic upregulation of ACE2 and TMPRSS2 in conjunction with an elevated proinflammatory state as assessed by the high liver expression of IL-6, IL-8, and MCP-1. This might explain in part why cirrhotic patients are predisposed to a severe COVID-19 outcome, and why, following SARS-COV-2 infection, hepatic decompensation and ACLF can ensue, which could contribute to the increased mortality observed in these patients. This work was supported by the grant # 652260 from Consejo Nacional de Ciencia y Tecnología (CONACYT)-México (N.N.A). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Consejo Nacional de Ciencia y Tecnología. The authors declare no conflict of interest that pertain to this work. The data that support the findings of this study are available from the corresponding author upon reasonable request. Nathaly Limon-de la Rosa, Eduardo Cervantes-Alvarez, Nalu Navarro-Alvarez Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19 An inflammatory cytokine signature predicts COVID-19 severity and survival SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Cholangiocyte proliferation and liver fibrosis Findings of Hepatic Severe Acute Respiratory Syndrome Coronavirus-2 Infection Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients Acute-onchronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis